Heath K J, Sampson M J, Ridley S A
Department of Anaesthesia, Addenbrooke's Hospital, Cambridge, UK.
Intensive Care Med. 1996 Oct;22(10):1096-7. doi: 10.1007/BF01699235.
We present the clinical case of a patient who was admitted to the intensive care ward with severe central nervous system symptoms and cardiovascular collapse within a week of starting sulphasalazine; in the absence of any other diagnosis, these symptoms were felt to be due to a previously unreported adverse effect of sulphasalazine.
我们报告了一例患者的临床病例，该患者在开始服用柳氮磺胺吡啶一周内因严重的中枢神经系统症状和心血管衰竭入住重症监护病房；在没有其他诊断的情况下，这些症状被认为是由柳氮磺胺吡啶以前未报告的不良反应所致。
